Last mentioned: Mar 12, 2026
Motion to Dismiss Phase
Defendants expected to file motions to dismiss based on Safe Harbor protections for forward-looking statements.
Lead Plaintiff Deadline (Est.)
Typical 60-day window for investors to petition the court to lead the consolidated class action.
Litigation Commencement
Schall Law Firm announces class action lawsuits against both SLNO and RARE.
Investor Alerts Issued
Pomerantz Law Firm releases multiple reminders for class action deadlines across the biotech sector.
Soleno Executive Turnover
Official filing confirms the departure of several directors and officers.
Soleno Financial Results
Soleno files annual results and operational updates.
Ultragenyx Restructuring Disclosure
Company files SEC report detailing costs for exit or disposal activities.
The Schall Law Firm has initiated securities fraud class action lawsuits against biotech players Soleno Therapeutics and Ultragenyx Pharmaceutical. The legal actions follow a series of corporate disclosures in early 2026, inviting impacted investors to lead the litigation efforts.
Pomerantz Law Firm has issued urgent reminders to investors regarding class action deadlines for Ultragenyx, Mereo BioPharma, Navan, and Fermi. These legal actions follow allegations of misleading statements and failures to disclose material risks concerning clinical data and financial projections.
This page surfaces every story mentioning Ultragenyx Pharmaceutical Inc. across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Ultragenyx Pharmaceutical Inc. was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |